Julius Clinical is proud to announce our continued sponsorship of Bio-Neuroscience 2025, the premier summit for CEOs, investors, and industry decision-makers in CNS neuroscience drug development. Taking place in Amsterdam from 25-27 February 20...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius Clinical There is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
At Julius Clinical, we are proud to announce the first formal meeting of our Dementia Scientific Advisory Board (SAB) with Prof. Philip Scheltens and Prof. John Harrison—a major milestone in our commitment to advancing dementia research and clin...
From being a largely unknown pathogen, Respiratory Syncytial Virus (RSV) is now almost a household word – and a fearful one for families with infants and young children at risk. But new solutions, such as long-acting monoclonal antibodies (mAbs)...
At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR trial outcomes. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascu...
Zeist, Netherlands, April 22, 2024 — We proudly welcome Stefan Timmerman as our new Chief Financial Officer (CFO), effective April 1st, following up Eelco Brouwer, who played a crucial role in the completion of the Ampersand transaction last yea...
Zeist, Netherlands, April 5, 2024 — We’re proud to announce the appointment of Ricard Quingles Blasi as our new Chief Business Officer (CBO). With over 25 years of dynamic leadership experience, Ricard Quingles Blasi brings a wealth of strate...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius Clinical The estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...
Utrecht, The Netherlands, 05-02-2024 GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in the detection and treatment of Metabolic Dysfunc...
Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners Partnership will further expand Julius’ clinical trial services capabilities to advance new therapeutics. Zeist, Netherlands, November 28, 2023 -- Julius Cli...
"*" indicates required fields
"*" indicates required fields
